Establishing a Quality Control System for Stem Cell-Based Medicinal Products in China

Area of Science:

• Regenerative Medicine
• Biotechnology
• Regulatory Science

Background:

• Stem cell-based medicinal products (SCMPs) represent a promising frontier in therapeutics.
• Effective quality control is paramount for SCMP development, encompassing technologies, standards, and regulatory compliance throughout the product lifecycle.
• A globally harmonized, robust quality control system for SCMPs remains underdeveloped due to scientific knowledge gaps and technological limitations in assessing safety and efficacy.

Purpose of the Study:

• To review the regulatory landscape and quality control considerations for SCMPs in China, focusing on nonhematopoietic stem cells.
• To discuss principal quality attributes and propose testing strategies for SCMPs.
• To identify regulatory and technical challenges hindering the establishment of a comprehensive SCMP quality control system.

Main Methods:

• Review of existing regulations and technical guidelines for cell therapy products in China.
• Analysis of quality attributes specific to nonhematopoietic SCMPs.
• Discussion of proposed testing approaches and evaluation technologies for SCMP quality control.

Main Results:

• China has initiated efforts to establish SCMP quality control through interim guidelines and technological advancements.
• Key quality attributes and potential testing methodologies for SCMPs have been outlined.
• Significant regulatory and technical hurdles remain in developing a comprehensive quality control framework.

Conclusions:

• Advancing stem cell regulatory science through collaborative efforts is essential for creating an effective SCMP quality control system.
• The development of standardized quality control technologies and guidelines is critical for ensuring the safety and efficacy of SCMPs.
• Continued research and regulatory harmonization are needed to fully realize the therapeutic potential of SCMPs.